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The immunostimulatory properties of radiation therapy (RT) have recently generated 
widespread interest due to preclinical and clinical evidence that tumor-localized RT 
can sometimes induce antitumor immune responses mediating regression of non-
irradiated metastases (abscopal effect). The ability of RT to activate antitumor T cells 
explains the synergy of RT with immune checkpoint inhibitors, which has been well 
documented in mouse tumor models and is supported by observations of more 
frequent abscopal responses in patients refractory to immunotherapy who receive RT 
during immunotherapy. However, abscopal responses following RT remain relatively 
rare in the clinic, and antitumor immune responses are not effectively induced by RT 
against poorly immunogenic mouse tumors. This suggests that in order to improve the 
pro-immunogenic effects of RT, it is necessary to identify and overcome the barriers 
that pre-exist and/or are induced by RT in the tumor microenvironment. On the one 
hand, RT induces an immunogenic death of cancer cells associated with release of 
powerful danger signals that are essential to recruit and activate dendritic cells (DCs) 
and initiate antitumor immune responses. On the other hand, RT can promote the 
generation of immunosuppressive mediators that hinder DCs activation and impair the 
function of effector T  cells. In this review, we discuss current evidence that several 
inhibitory pathways are induced and modulated in irradiated tumors. In particular, we 
will focus on factors that regulate and limit radiation-induced immunogenicity and 
emphasize current research on actionable targets that could increase the effectiveness 
of radiation-induced in situ tumor vaccination.
Keywords: abscopal effect, adenosine, hypoxia, immunotherapy, macrophages, radiation therapy, transforming 
growth factor-β, tumor microenvironment
iNTRODUCTiON
Immune checkpoint blockade with antibodies targeting cytotoxic T  lymphocyte-associated pro-
tein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) has shown durable responses in 
a significant portion of patients with metastatic cancer. However, patients that lack pre-existing 
antitumor immunity are generally unresponsive to these therapies (1). In these patients, treatment 
with immune checkpoint inhibitors needs to be combined with a strategy to induce de novo tumor-
specific T cells. Recent findings have shed light on the potential of radiation therapy (RT) to induce 
such responses (2).
FiGURe 1 | immunosuppressive pathways enhanced by RT in the TMe that limit RT-induced in situ vaccination. (A) DCs are recruited to the tumor and 
activated following RT-mediated induction of ICD and subsequent release of DAMPs in the TME [including ATP, depicted in (e)]. After uptake of TAAs that are 
released from dying tumor cells DCs become activated and migrate to tumor-draining lymph nodes where they cross-present the antigens to naïve T cells. The 
activated TAA-specific CD8+ T cells proliferate, acquire effector function, and infiltrate the irradiated tumor and abscopal sites where they eliminate tumor cells. 
However, RT promotes not only immune stimulation but also contributes to a suppressive TME that counteracts the newly initiated immune response. (B) Hypoxic 
regions within tumors have reduced sensitivity to RT and a suppressive TME that can be exacerbated following RT. RT upregulates transcription of HIF-1α resulting 
in expression of a series of genes that promote immunosuppression, by inducing Treg proliferation, M2 polarization of TAMs, and MDSC activation. (C) C–C 
chemokine receptor type 2 (CCR2)-expressing monocytes are recruited to the tumor due to increased CCL2 levels following RT. In the tumor, monocytes then 
differentiate to TAMs. RT can also directly modulate TAMs through induction of CSF1 causing mobilization, proliferation, and polarization of TAMs to an M2 
phenotype. (D) RT activates latent TGFβ within the tumor that causes conversion of CD4+ T cells to Tregs, and polarization of TAMs and TANs to an M2 and N2 
phenotype, respectively. (e) Tumor cells undergoing radiation-induced ICD release ATP, which is rapidly catabolized into adenosine in the TME by ectoenzymes 
CD39 and CD73 expressed on tumor cells, stromal cells, and immune cells. Local accumulation of extracellular adenosine suppresses DCs and effector T cells 
while promoting proliferation of Tregs and a more suppressive phenotype in TAMs. DC, dendritic cell; ICD, immunogenic cell death; RT, radiation therapy; DAMPs, 
danger-associated molecular patterns; TAA, tumor-associated antigens; TME, tumor microenvironment; pMHC-1, peptide-loaded major histocompatibility class I 
complex; TCR, T cell receptor; HIF-1α, hypoxia-inducible factor-1α; VEGFA, vascular endothelial growth factor A; CTLA-4, cytotoxic T lymphocyte-associated 
protein 4; PD-1, programmed cell death protein-1; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; LAG-3, lymphocyte-activation gene 3; Treg, 
regulatory T cell; TGFβ, transforming growth factor β; TAM, tumor-associated macrophage; MDSC, myeloid-derived suppressor cell; CSF1, colony-stimulating factor 
1; TAN, tumor-associated neutrophil; ATP, adenosine triphosphate.
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Exposure of tumor cells to ionizing radiation (or certain 
cytotoxic chemotherapy agents) can result in immunogenic 
cell death (ICD) whereby upregulation or release of danger-
associated molecular patterns (DAMPs) including calreticulin, 
high-mobility group protein B1, and adenosine triphosphate 
(ATP) alerts the immune system of a potential threat (3, 4). 
The release of DAMPs associated with RT-induced cancer cell 
death occurs in a dose-dependent fashion and has been shown 
to both recruit and activate dendritic cells (DCs) to uptake 
tumor antigens and cross-present them to naïve T  cells thus 
initiating antitumor immune responses (Figure 1) (5–9). RT can 
also facilitate the recruitment of effector T-cells to the tumor 
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by inducing the secretion of CXC motif chemokine ligand 
(CXCL)9, CXCL10, and CXCL16 by tumor cells (10–12). In 
addition, RT-induced upregulation of major histocompatibility 
complex class I molecules, FAS/CD95, and stress-induced natu-
ral killer group 2D-ligands on tumor cells enhance recognition 
and killing of cancer cells by cytotoxic T  cells (CTLs) (10, 
13–15). Overall, these RT-induced signals have been shown 
to mediate, at least in part, the powerful synergy between RT 
and a variety of immune therapeutic agents, including immune 
checkpoint inhibitors and DC growth factors, in experimental 
settings where these treatments by themselves were ineffective. 
The most important result of this synergy is immune-mediated 
tumor regression in non-irradiated metastases, known as 
abscopal effect, which has been seen in preclinical models 
as well as patients and supports the interpretation that the 
irradiated tumor acts as an in situ vaccine generating a systemic 
antitumor response (16–21). However, abscopal effects remain 
rare, highlighting the need to better understand and address 
the obstacles to effective in  situ vaccination by RT.
Once tumors are established, they have evolved multiple ways 
to escape immune-mediated control and elimination, often by 
creating an increasingly immunosuppressive microenvironment 
(22). Myeloid cells in the tumor microenvironment (TME) are 
polarized toward an immunosuppressive phenotype, and DCs 
acquire a tolerogenic function or are excluded altogether from 
the tumor (23). If effector T cells are present, they are unable to 
function due to inhibitory molecules expressed on tumor and 
stromal cells and/or a suppressive cytokine milieu (22). There 
are multitudes of signaling pathways that govern the suppressive 
nature of the TME, and the modulation of these pathways by RT 
is an active area of study.
Tumors, which often behave like non-healing wounds, are 
rich in tumor-associated macrophages (TAMs), whose sup-
pressive properties are largely regulated by colony-stimulating 
factor 1 (CSF1), a growth factor that is upregulated in irradi-
ated tumors (24). TAMs secrete transforming growth factor-β 
(TGFβ) and other cytokines that suppress effector T cells and 
stimulate regulatory T  cells (Tregs). The TME contains large 
amounts of inactive TGFβ, which can be converted to its active 
form by RT, as discussed below. In addition to its stimula-
tory effect on tumor angiogenesis, fibrosis, and cell growth, 
TGFβ has direct inhibitory effects on the antitumor immune 
response. Under conditions of hypoxic stress, which occurs 
commonly in growing tumors and can be further exacerbated 
following RT, tumor cells utilize hypoxia-inducible factors 
(HIFs) to induce expression of genes that help them cope 
metabolically with the low oxygen levels and vascularize the 
tumor tissue, including vascular endothelial growth factor A 
(VEGF-A). Moreover, the hypoxic TME contains high levels 
of adenosine, a pleiotropic immunosuppressive mediator that 
can be actively secreted from intracellular stores or generated 
by extracellular catabolism of ATP released following cellular 
stress including RT-induced ICD (5, 25). In this review, we 
will discuss how RT regulates these fundamental immunosup-
pressive pathways, how they interact and affect each other and 
importantly, how they modulate the ability of RT to induce 
antitumor immunity.
ReGULATiON OF TAMs iN THe 
iRRADiATeD TUMOR
TAMs comprise a major component of the inflammatory 
infiltrate in many solid tumors and for the most part promote 
a tolerogenic and immunosuppressive milieu. Their presence 
in ovarian, prostate, cervical, and breast malignancies is cor-
related with poor prognosis (26). TAMs can acquire functional 
properties that span the spectrum from M1 to M2-type tissue 
macrophages. Classically activated (M1) macrophages are highly 
phagocytic toward tumor cells, present antigens effectively and 
secrete pro-inflammatory cytokines essential for the recruitment 
and activation of T and natural killer (NK) cells (27). In contrast, 
under the influence of a Th2-type cytokine environment, mac-
rophages become alternatively activated (M2) and perform tissue 
remodeling and immunosuppressive functions promoting tumor 
progression. In most tumor studies, TAMs have been shown 
to promote tumor invasion and metastasis (28, 29). This pro-
tumorigenic phenotype is highly influenced by the progressively 
growing tumor and by soluble factors secreted by both cancer 
cells and other infiltrating immune cells (30).
TAMs produce high levels of immunosuppressive IL-10 and 
stimulate angiogenesis that further supports tumor growth (31). 
However, in some malignancies such as lung and gastric cancer, 
the presence of TAMs correlated with a more favorable patient 
outcome, suggesting a high functional plasticity of TAMs, which 
may acquire M1-like properties in some tumors. Importantly, 
radiation can profoundly modulate TAM populations in several 
ways (a) it depletes TAM as well as immature myeloid cells, (b) 
it increases their recruitment, (c) it causes their re-distribution 
between areas of necrosis and hypoxia elicited by RT, (d) it 
changes their polarization toward either M1 or M2 phenotype, 
and (e) it improves the ability of macrophages to present tumor 
antigens (32, 33).
Although the molecular mechanisms that underlie the ability 
of radiation to provoke these effects remain incompletely defined, 
the activation of the signaling pathway mediated by the growth 
factor CSF1 plays a critical role. Binding of CSF1 to its cognate 
receptor tyrosine kinase colony-stimulating factor 1 receptor 
(CSF1R) rapidly initiates the proliferation, differentiation, and 
migration of tissue-resident macrophages (Figure  1) (34, 35). 
The CSF1/CSF1R pathway is critical in recruiting TAMs and 
promoting tumor growth. In patients with breast, prostate, and 
ovarian cancer, high CSF1 levels have been shown to correlate 
with poor prognosis (36–38). Furthermore, the prognostic value 
of a CSF1-responsive gene signature was validated in a subset 
of breast cancer patients, where it was shown to predict risk of 
recurrence and invasiveness (39, 40). The expression of CSF1 in a 
broad array of human and murine tumor cell lines was increased 
after irradiation in vitro as well as in vivo in implanted tumors 
(24). An increase in the levels of serum CSF1 was observed in 
prostate cancer patients receiving radiotherapy, suggesting that 
the radiation-induced CSF1 upregulation is clinically relevant. 
The molecular mechanism of RT-induced CSF1 upregulation 
was recently described in a mouse prostate carcinoma. The non-
receptor tyrosine kinase ABL1, which mediates apoptosis and 
cell cycle arrest and is activated following radiation, was shown 
TABLe 1 | Comprehensive summary of clinical trials associated with immunosuppressive pathways regulated by radiation therapy (RT).
Pathway 
targeted
immunotherapy RT regimen Condition Status and phase identifier
TGFβ-mediated 
inhibition
Galunisertib (LY2157299)—TGFβ antagonist Stereotactic body 
radiotherapy
Hepatocellular 
carcinoma
Not yet recruiting  
(Phase 1)
NCT02906397
Galunisertib (LY2157299)—TGFβ antagonist 7.5 Gy × 3 fractions Breast cancer Recruiting (Phase 2) NCT02538471
Fresolimumab (GC1008)—TGFβ antagonist 7.5 Gy × 3 fractions Breast cancer Ongoing (Phase 2) NCT01401062
Galunisertib (LY2157299)—TGFβ antagonist 1.8–2.0 Gy × 30 fractions Malignant glioma Ongoing (Phase 1–2) NCT01220271
Fresolimumab (GC1008)—TGFβ antagonist Stereotactic ablative 
radiotherapy
Non-small cell lung 
carcinoma
Recruiting (Phase 1–2) NCT02581787
Tumor-
associated 
macrophages-
recruitment and 
polarization
Pexidartinib (PLX3397)—CSF1R inhibitor Yes (dose not determined) Prostate cancer Recruiting (Phase 1) NCT02472275
Pexidartinib (PLX3397)—CSF1R inhibitor 60 Gy (5 days/week for 
6 weeks)
Glioblastoma Ongoing (Phase 1–2) NCT01790503
Pexidartinib (PLX3397)—CSF1R inhibitor No RT Tenosynovial giant cell 
tumor
Ongoing (Phase 3) NCT02371369
Carlumab (CNTO 888)—anti-CCL2 monoclonal 
antibody
No RT Prostate cancer Completed (Phase 2) NCT00992186
Adenosine-
mediated 
inhibition
MEDI9447—CD73 inhibitor No RT Advanced solid 
tumors
Recruiting (Phase 1) NCT02503774
Tozadenant (SYN115)—A2AR antagonist No RT Parkinson’s disease Completed (Phase 2–3) NCT01283594
VEGF-A/HIF-
1α-mediated 
inhibition
Bevacizumab—anti-VEGF monoclonal antibody Yes (dose not determined) Glioblastoma 
multiforme
Ongoing (Phase 0) NCT01091792
Sorafenib—protein kinase inhibitor targeting 
VEGF receptor
1.8 Gy daily for 5 weeks Pancreatic cancer Completed (Phase 1) NCT00375310
Bevacizumab—anti-VEGF monoclonal antibody, 
Temozolomid
60 Gy (5 days/week for 
6 weeks)
Glioblastoma Ongoing (Phase 3) NCT00884741
Bevacizumab—anti-VEGF monoclonal antibody, 
Ipilimumab—anti-CTLA-4 monoclonal antibody
No RT Metastatic melanoma Ongoing (Phase 1) NCT00790010
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to translocate to the nucleus and bind to the CSF1 promoter 
region. Importantly, blocking the CSF1/CSF1R signaling pathway 
using either a selective inhibitor (GW2580) or a highly potent 
small molecule inhibitor of CSF1R kinase (PLX3397) resulted in 
significant reduction in TAM infiltration and improved tumor 
control by RT in a mouse model (24), suggesting that the CSF1/
CSFR1 axis is an important therapeutic target.
Another chemokine implicated in the RT-induced myeloid 
cell recruitment to the tumor is C-C motif ligand 2 (CCL2). In a 
mouse tumor model of pancreatic adenocarcinoma (PDAC), local 
delivery of a single 20 Gy dose markedly augmented the release 
of CCL2 by tumor cells, which was consequently accompanied 
by the infiltration of inflammatory macrophages expressing C-C 
chemokine receptor type 2 (CCR2, the cognate receptor for CCL2) 
(Figure 1) (41). The mobilization of inflammatory monocytes via 
CCL2/CCR2 axis has been described as a negative prognosticator 
in breast, pancreatic, and hepatocellular cancer, and its activation 
may further play a key role in mediating resistance of PDAC to 
ablative radiotherapy (28, 42, 43). These findings suggest that 
CCL2/CCR2 antagonists currently under clinical evaluation may 
have a new role in the context of radiotherapy, where they could 
be used to improve patient responses (Table 1) (44–46).
HYPOXiA iN RT-TReATeD TUMORS 
AND iMMUNe ReGULATiON BY HiF-1α 
AND veGF-A
Perturbation in oxygen homeostasis is a common feature of solid 
tumors, in which hypoxic regions are more resistant to RT. Indeed, 
ionizing radiation creates free radicals that are highly reactive due 
to their unpaired electrons and can therefore react with molecular 
oxygen leading to the production of reactive oxygen species 
(ROS). High concentrations of ROS, such as superoxide anion 
radical or hydrogen peroxide, can initiate harmful chemical 
reactions within the cells, including DNA damage. Thus, well-
oxygenated cancer cells are more sensitive to cytocidal effects of 
RT than hypoxic cells.
Hypoxia-inducible factor-1α (HIF-1α) is a key transcription 
factor induced by hypoxia that has been reported to correlate 
with a poor prognosis, local tumor recurrence, and distant tumor 
metastases after RT (47, 48). Upregulation of HIF-1α in response 
to RT enhances endothelial cell radioresistance (49). Irradiation 
induces the stabilization of HIF-1α protein in glioma cells, thereby 
promoting angiogenesis and malignant progression (50). HIF-1α 
regulates multiple genes and signaling pathways including cancer 
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cell survival, tumor neovascularization, and metabolism, which 
directly and indirectly impact antitumor immunity. Hypoxia can 
interfere with T  cell effector function by selectively upregulat-
ing programmed death-ligand 1 (PD-L1) expression on both 
tumor cells and myeloid-derived suppressor cells (MDSCs) in a 
HIF-1α-dependent manner. Blockade of PD-L1 under hypoxia 
prevents T cell apoptosis and abrogates MDSC-mediated T cell 
suppression by modulating MDSCs cytokine production (51, 52).
Accumulating evidence indicates that hypoxia can also con-
tribute to immune tolerance by regulating immunosuppressive 
cell populations. Facciabene et al. have demonstrated that hypoxic 
tumors promote the recruitment of Tregs via CCL28, which, in 
turn, dampen effector T cell function and promote angiogenesis 
(53). TAMs have been shown to inhibit T-cell proliferation under 
hypoxia in a HIF-1α-dependent manner in the murine MMTV-
PyMT model of breast cancer. Furthermore, targeted deletion of 
HIF-1α in myeloid cells resulted in reduced tumor growth (54). 
Although tumor hypoxia does not influence the differentiation 
and/or polarization of TAMs, it does fine-tune the phenotype of 
the M2-like macrophage population (55). HIF-1α also regulates 
MDSCs differentiation and function in the TME (51, 56). Sceneay 
et al. have also reported that factors secreted by hypoxic tumors 
(driven by HIF-1α signaling) condition the establishment of the 
premetastatic niche by recruiting granulocytic MDSCs and sup-
pressing NK cell cytotoxicity (57).
As mentioned above, one important role of HIF-1α is the 
stimulation of angiogenesis (58–60). In the absence of oxygen, 
HIF-1α binds to hypoxia-response elements, thereby activating 
the expression of multiple hypoxia-response genes, including 
VEGF-A, which is produced by a majority of tumor cells, is 
present in the serum of cancer patients and whose expres-
sion is increased by RT (Figure  1) (61, 62). In addition to 
its direct pro-angiogenic properties, VEGF-A is also a potent 
immunosuppressive mediator in the TME. VEGFR2, one of its 
two key receptors, is selectively expressed by Foxp3high CD4+ 
Tregs and VEGF-A has been shown to induce Treg proliferation 
in a VEGFR2-dependent manner in tumor-bearing mice and 
metastatic colorectal cancer patients (63, 64). VEGF-A arrests 
the differentiation of myeloid cells, resulting in the accumula-
tion of MDSCs (65, 66). Horikawa et al. have shown recently that 
the VEGF-A/VEGFR2 pathway increases intratumoral MDSCs 
and promotes tumor progression in a mouse ovarian cancer 
model. They also showed that VEGF expression correlated with 
MDSCs infiltration in human samples from the peritoneum of 
ovarian cancer patients with disseminated disease (67). Besides 
these effects on immunoregulatory cells, a direct inhibition 
of conventional T  cells by VEGF-A has been reported (68). 
VEGF-A also enhances the expression of inhibitory receptors 
by CD8+ T cells (Tim-3, CTLA-4, PD-1, Lag-3) in a VEGFR2-
NFAT-dependent manner. Treatment of CT26 tumor-bearing 
mice with VEGF-A antibody decreases the expression of these 
inhibitory receptors on CD8+ T  cells isolated from the tumor 
and from hepatic metastases (69). Recently, Motz et  al. have 
demonstrated that VEGF-A together with IL-10 and PGE2 in 
hypoxic regions can induce Fas ligand expression on tumor 
endothelial cells, leading to the apoptosis of effector CD8+ 
T  cells (70).
Altogether, these data suggest that VEGF-targeted therapies 
could reverse immunosuppression and increase antitumor 
immunity. Notably, inhibiting VEGF-A pathway by neutralizing 
antibodies has been shown to increase the antitumor effects of 
ionizing radiation (71, 72). Currently, the most prominent VEGF 
pathway-targeting drug is bevacizumab; a recombinant human-
ized monoclonal antibody that binds to human VEGF-A. A 
combinatorial therapy targeting tumor hypoxia by using HIF-1α 
or VEGF-A inhibitors along with RT and immunotherapy (PD-
L1 or other immune checkpoint inhibitor) may be beneficial for 
enhancing antitumor immunity in cancer patients.
DUAL ROLe OF ADeNOSiNeRGiC 
SiGNALiNG iN TUMORS FOLLOwiNG RT
Adenosine accumulation in the TME has been identified as a 
central immunosuppressive factor (73, 74). ATP is the universal 
carrier of chemical energy and is present in all metabolically 
active cells. When released into the extracellular space follow-
ing ICD, ATP triggers recruitment of DCs, and other antigen-
presenting cells through P2Y2 receptor-dependent chemotaxis 
(75). In addition, ATP constitutes an important activation signal 
for DCs by activating the NLRP3 inflammasome through ligation 
with the P2RX7 receptor (76). DCs are stimulated to produce 
pro-inflammatory cytokines IL-1β and IL-18, and they start to 
differentiate, allowing them to process engulfed tumor antigens, 
and migrate to the draining lymph nodes to cross-present the 
antigens to naïve T cells (6, 77, 78).
RT has been shown to trigger release of ATP from tumor 
cells in a dose-dependent manner suggesting that ATP is a key 
mediator of radiation-induced antitumor immunity (5). However, 
ATP is rapidly catabolized in the TME by the action of ectonu-
cleotidases CD39 (ecto-nucleoside triphosphate diphosphohy-
drolase 1) that catalyzes the hydrolysis of ATP into adenosine 
diphosphate (ADP) and ADP into adenosine monophosphate 
(AMP). AMP is then converted into adenosine by irreversible 
hydrolysis catalyzed by CD73 (ecto-5′-nucleotidase), the rate-
limiting enzyme for adenosine generation (79). Adenosine is 
a pleiotropic anti-inflammatory mediator that directly inhibits 
the activity of antigen-presenting cells and effector lymphocytes, 
primarily through uptake via adenosine receptor 2A (A2AR), and 
also indirectly by promoting proliferation of Tregs and skewing 
the polarization of TAMs from an M1 to an M2 phenotype 
(Figure  1) (80–82). Moreover, the expression of A2AR is 
upregulated under hypoxic conditions (83).
CD73 is expressed in a multitude of cancers and its sig-
nificance in tumor progression is supported by studies showing 
that CD73 expression levels correlated with worse prognosis in 
triple-negative breast cancer as well as in gastric, colorectal, and 
gallbladder cancer (84–87). Moreover, preclinical studies have 
revealed that CD73-deficient mice have a suppressed growth 
of implanted tumors and are protected from experimental 
metastases (88). Although the expression of CD39 has not yet 
been correlated with tumor behavior or stage in patients, CD39 
is overexpressed in some human tumor cells and co-culture 
of CD39+ tumor cells with activated CD4+ and CD8+ T  cells 
suppressed T  cell proliferation, which was abrogated in the 
6Wennerberg et al. Barriers to Radiation-Induced In Situ Tumor Vaccination
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 229
presence of CD39-blocking antibody or A2AR inhibitor (89). 
Interestingly, CD39 and CD73 are also expressed by effector 
T cells, and their expression is regulated by the concentration of 
ATP metabolites in the extracellular milieu (90). Expression of 
CD39 and CD73 in Tregs correlates with their suppressive capac-
ity, highlighting the plasticity and importance of adenosinergic 
signaling in regulating immune activation (91–94). Moreover, 
MDSCs express CD39 and CD73 and are sensitive to adenosine 
signaling, which affects their function and migration (95, 96). 
The suppressive activity of granulocytic MDSCs is increased in 
presence of AMP in vitro (97).
Stagg and colleagues have shown that pharmacological 
blockade of adenosine generation or uptake, by inhibition of 
CD73 or A2AR, respectively, promotes antitumor immune 
responses and synergizes with anti-PD-1 and anti-CTLA-4 
(98–100). To date, little is known of the interplay between radia-
tion and adenosine-mediated immunosuppression. However, 
our data suggest that the dose-dependent release of ATP fol-
lowing tumor irradiation along with a high ectonucleotidase 
expression in the TME may lead to increased adenosine levels 
following RT and limit the efficacy of radiation-induced in situ 
tumor vaccination (101).
TGFβ AS A CeNTRAL ReGULATOR OF 
RT-iNDUCeD TUMOR iMMUNOGeNiCiTY
TGFβ is a multipotent cytokine involved in the regulation of 
cellular differentiation, survival, and function of many, if not 
all, immune-cell types (102–106). For instance, approximately 
25 years ago, Shull and colleagues reported a massive activation 
and expansion of T  cells in TGFβ1-deficient mice, indicating 
that one of the major roles of TGFβ is the regulation of T cell 
differentiation and function (107). Since then, TGFβ has been 
demonstrated to inhibit the functional differentiation of CD8+ 
T cells into CTLs and to actively contribute to the conversion of 
naïve CD4+ T cells into Tregs upon TCR cross-linking (108–110). 
TGFβ has also been reported to induce expression of CD73, and 
to a lesser extend CD39 in both CD4+ and CD8+ T cells (111). 
Chalmin and colleagues have corroborated these findings by 
showing that the expression of CD39 and CD73 is under TGFβ 
transcriptional control in in vitro generated Th17 cells via Stat3 
activation (112).
Immune regulation mediated by TGFβ extends far beyond the 
T cell compartment with TGFβ playing a key role in subverting 
adaptive immunity by inhibiting DCs activation and skewing the 
phenotype of macrophages from M1 to M2 (113–116). Importantly, 
aside from their well-described role in host defenses, accumulat-
ing evidence indicate that neutrophils exhibit a high phenotypic 
and functional plasticity depending upon TGFβ available in the 
TME (117). Indeed, similar to macrophages, TGFβ has been 
shown to drive the phenotype change of a more tumor cytotoxic 
and pro-inflammatory phenotype (N1) into a tumor supportive 
phenotype (N2) (113). Radiation activates latent TGFβ through a 
conformational change of the latency-associated peptide–TGFβ 
complex releasing active TGFβ (Figure 1) (118, 119).
The role of TGFβ as a master regulator of RT-induced 
antitumor T  cell responses was demonstrated in two mouse 
tumor models of breast cancer. Antibody-mediated neutraliza-
tion of TGFβ was required to achieve RT-induced priming 
of CD8 T  cells to multiple endogenous tumor antigens. 
Importantly, complete regression of the irradiated 4T1 tumor 
and inhibition of spontaneous lung metastases was seen only 
in mice treated with RT in the presence of TGFβ neutraliza-
tion and was mediated by T  cells. Likewise, effective growth 
inhibition of non-irradiated synchronous subcutaneous TSA 
tumors required TGFβ neutralization together with RT to 
the contralateral TSA tumor, demonstrating an abscopal 
effect (120). These data highlight the importance of TGFβ-
mediated immunosuppression in the context of the irradiated 
tumor. While concurrent blockade of TGFβ with RT-achieved 
therapeutically effective antitumor immune responses able to 
extend mice survival, upregulation of PD-L1 in the irradi-
ated tumor, detected on both carcinoma cells and infiltrating 
myeloid cells, was found to limit tumor rejection, leading 
to early tumor recurrence. Upregulation of PD-L1-following 
RT has been reported in several preclinical studies and is 
mediated via at least two distinct mechanisms. In relatively 
immunogenic tumors, RT alone was able to elicit antitumor 
T  cells that infiltrated the tumor and produced interferon-γ 
(IFNγ), which in turn induced PD-L1 expression on tumor 
cells (120, 121). Similarly, PD-L1 upregulation was driven by 
effector T  cell infiltration in a poorly immunogenic tumor 
after RT plus TGFβ blockade (120).
These data suggest that when RT alone or in combination with 
an immune modulator elicits T cell responses that are insufficient 
to reject the tumor, the upregulation of immune checkpoint mol-
ecules in response to immune attack limits tumor rejection (122). 
As discussed above, another mechanism of PD-L1 upregulation 
is mediated by RT-induced HIF-1α (51, 123). Thus, PD-1/PD-L1 
axis may represent an important obstacle to RT-induced tumor 
rejection, a hypothesis currently being tested in several clinical 
studies (124).
USiNG RADiOTHeRAPY TO eNHANCe 
ReSPONSeS TO iMMUNOTHeRAPY iN 
THe CLiNiC
Several therapeutics designed to counteract the accumulation or 
action of immunosuppressive mediators are undergoing testing 
in cancer patients, in some cases in combination with RT. Table 1 
provides examples of clinical trials that investigate drugs targeting 
the suppressive pathways discussed above. We have not included 
trials testing RT with anti-PD-1 or anti-PD-L1 since the latter 
were discussed in several recent reviews (124–126).
Antiangiogenic therapy in the form of the anti-VEGF-A 
antibody bevacizumab has been tested in combination with the 
anti-CTLA-4 antibody ipilimumab in patients with metastatic 
melanoma demonstrating favorable clinical outcomes and 
was associated with improved tumor T  cell infiltration (127, 
128). Preclinical studies in colorectal cancer xenografts have 
demonstrated that inhibition of the VEGF receptor (VEGFR) 
with concomitant fractionated RT resulted in normalization 
of vasculature and improved tumor control compared to RT 
or VEGFR-inhibition alone (129). Hyperfractionated RT is 
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currently being combined with bevacizumab in glioblastoma 
patients and with sorafenib (a protein kinase inhibitor targeting 
VEGFR) in patients with pancreatic cancer (NCT00884741, 
NCT00375310).
The central role of TGFβ in modulation of RT-induced 
tumor immunogenicity has prompted the combined use of RT 
and TGFβ-inhibitors in clinical cancer trials. Following the 
development of the small molecule inhibitor of TGFβ-receptor 
I galunisertib (LY2157299), its safety profile has been tested in 
clinical trials, where intermittent administration was shown to 
be safe in patients with advanced cancer (130, 131). TGFβ neu-
tralization by the monoclonal antibody Fresolimumab (GC1008) 
was also shown to be without dose-limiting toxicity up to 15 mg/
kg in malignant melanoma and renal cell carcinoma (132). 
Fresolimumab is currently being tested in combination with 
hypofractionated RT in patients with metastatic breast cancer 
and lung cancer (NCT01401062, NCT02538471).
Inhibition of TAM recruitment or activation in solid tumors 
as a measure to reduce immune suppression and favor immune-
mediated antitumor activity is a promising therapeutic concept 
(36, 133). A phase I–II study of the CSF1R inhibitor PLX3397, 
which included 23 patients with advanced tenosynovial giant-cell 
tumors in the extension phase II part, showed promising results, 
with 12 patients having a partial response and 7 patients with 
stable disease. The median duration of responses was 8 months 
at the time of data cutoff (134). The CSF1R inhibitor PLX3397 
is currently under investigation in patients with prostate cancer 
and glioblastoma in combination with RT (NCT02472275, 
NCT01790503). Moreover, safety and tolerability of an anti-CCL2 
monoclonal antibody (carlumab, CNTO 888) as single therapy is 
under investigation in metastatic and castrate resistant prostate 
cancer (NCT00992186).
Although adenosine blockade has not been clinically tested 
in patients receiving RT, inhibitors of both adenosine conver-
sion (anti-CD73 monoclonal antibodies) and adenosine uptake 
(A2AR-inhibitors) have been tested for safety and tolerability 
in patients with cancer and Parkinson’s disease, respectively 
(NCT02503774, NCT01283594). Also in development for poten-
tial use in cancer patients are antibodies targeting CD39, which 
could potentially provide the advantage of increasing extracel-
lular ATP released during RT-induced ICD while simultaneously 
limiting the generation of adenosine precursors (135).
CONCLUSiON
The use of localized RT as an adjuvant to immunotherapy with 
the goal of inducing in  situ tumor vaccination is a promis-
ing concept for the treatment of cancer patients who lack a 
pre-existing immune response against their tumor. However, 
successful induction of antitumor immunity by RT is dependent 
upon the balance of the pre-existing immunosuppressive factors, 
and the immunosuppressive and immune-activating signals that 
are generated by RT. Improved understanding of the specific 
pathways that are enabled by RT, and of their mode of action, 
provides several novel actionable targets for inhibition to aug-
ment radiation-induced tumor immunogenicity. More studies 
are warranted to determine how to best leverage the new role of 
RT as an inducer of antitumor T cells.
AUTHOR CONTRiBUTiONS
EW designed and wrote the manuscript. CL, CV-B, KP, EG-M, 
and N-PR contributed to writing the manuscript and preparing 
the illustration and table. SD and SF edited the manuscript. 
All authors have read and approved the final version of the 
manuscript.
FUNDiNG
SD is supported by grants from NIH (R01 CA201246 and 
R01 CA198533) and from The Chemotherapy Foundation. 
SF and SD are supported by a grant from the Breast Cancer 
Research Foundation and SF is further supported by a grant 
from DOD BCRP (BC100481/W81XWH-11-1-0530). CV-B is 
supported by a post-doctoral fellowship from the DOD BCRP 
(W81XWH-13-1-0012). EW is supported by a post-doctoral fel-
lowship from the DOD BCRP (BC160113). EG-M is supported 
by a grant from GEICAM.
ReFeReNCeS
1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the 
tumor microenvironment. Nat Immunol (2013) 14(10):1014–22. doi:10.1038/
ni.2703 
2. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an 
in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 84(4):879–80. doi:10.1016/j.
ijrobp.2012.06.020 
3. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel 
L, et  al. Immunogenic cell death modalities and their impact on can-
cer  treatment. Apoptosis (2009) 14(4):364–75. doi:10.1007/s10495-008- 
0303-9 
4. Frey B, Hehlgans S, Rödel F, Gaipl US. Modulation of inflammation by 
low and high doses of ionizing radiation: implications for benign and 
malign diseases. Cancer Lett (2015) 368(2):230–7. doi:10.1016/j.canlet. 
2015.04.010 
5. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, 
Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced 
immunogenic cell death. Oncoimmunology (2014) 3:e28518. doi:10.4161/
onci.28518 
6. Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, et  al. ATP-
dependent recruitment, survival and differentiation of dendritic cell pre-
cursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 
(2013) 2(6):e24568. doi:10.4161/onci.24568 
7. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. 
Radiation-induced immunogenic modulation of tumor enhances antigen 
processing and calreticulin exposure, resulting in enhanced T-cell killing. 
Oncotarget (2014) 5(2):403–16. doi:10.18632/oncotarget.1719 
8. Kulzer L, Rubner Y, Deloch L, Allgäuer A, Frey B, Fietkau R, et  al. 
Norm- and hypo-fractionated radiotherapy is capable of activating 
human dendritic cells. J Immunotoxicol (2014) 11(4):328–36. doi:10.3109/ 
1547691X.2014.880533 
9. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. 
The interaction between HMGB1 and TLR4 dictates the outcome of anti-
cancer chemotherapy and radiotherapy. Immunol Rev (2007) 220:47–59. 
doi:10.1111/j.1600-065X.2007.00573.x 
10. Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron 
TO, et  al. Radiation-induced CXCL16 release by breast cancer cells 
attracts effector T  cells. J Immunol (2008) 181(5):3099–107. doi:10.4049/
jimmunol.181.5.3099 
8Wennerberg et al. Barriers to Radiation-Induced In Situ Tumor Vaccination
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 229
11. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by 
radiation therapy mediate recruitment and effector function of CD8(+) 
T  cells. Cancer Immunol Immunother (2014) 63(3):259–71. doi:10.1007/
s00262-013-1506-7 
12. Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, et al. 
Definitive chemoradiation alters the immunologic landscape and immune 
checkpoints in head and neck cancer. Br J Cancer (2016) 115(2):252–60. 
doi:10.1038/bjc.2016.166 
13. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. 
Radiation-induced IFN-gamma production within the tumor microenvi-
ronment influences antitumor immunity. J Immunol (2008) 180(5):3132–9. 
doi:10.4049/jimmunol.180.5.3132 
14. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley 
EK, et al. Radiation modulates the peptide repertoire, enhances MHC class 
I expression, and induces successful antitumor immunotherapy. J Exp Med 
(2006) 203(5):1259–71. doi:10.1084/jem.20052494 
15. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, 
et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activ-
ity and CTL adoptive immunotherapy. J Immunol (2003) 170(12):6338–47. 
doi:10.4049/jimmunol.170.12.6338 
16. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing 
radiation inhibition of distant untreated tumors (abscopal effect) is immune 
mediated. Int J Radiat Oncol Biol Phys (2004) 58(3):862–70. doi:10.1016/j.
ijrobp.2003.09.012 
17. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, 
Formenti SC, et  al. Fractionated but not single-dose radiotherapy induces 
an immune-mediated abscopal effect when combined with anti-CTLA-4 
antibody. Clin Cancer Res (2009) 15(17):5379–88. doi:10.1158/1078-0432.
CCR-09-0265 
18. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal 
response to radiation and ipilimumab in a patient with metastatic non-small 
cell lung cancer. Cancer Immunol Res (2013) 1(6):365–72. doi:10.1158/2326-
6066.CIR-13-0115 
19. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. 
In situ vaccination with a TLR9 agonist induces systemic lymphoma regres-
sion: a phase I/II study. J Clin Oncol (2010) 28(28):4324–32. doi:10.1200/
JCO.2010.28.9793 
20. Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian 
M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulat-
ing factor to generate abscopal responses in patients with metastatic solid 
tumours: a proof-of-principle trial. Lancet Oncol (2015) 16(7):795–803. 
doi:10.1016/S1470-2045(15)00054-6 
21. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et  al. 
Immunologic correlates of the abscopal effect in a patient with melanoma. N 
Engl J Med (2012) 366(10):925–31. doi:10.1056/NEJMoa1112824 
22. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer 
immunoediting and its three component phases – elimination, equilib-
rium and escape. Curr Opin Immunol (2014) 27:16–25. doi:10.1016/j.
coi.2014.01.004 
23. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin sig-
nalling prevents anti-tumour immunity. Nature (2015) 523(7559):231–5. 
doi:10.1038/nature14404 
24. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling 
blockade stanches tumor-infiltrating myeloid cells and improves the effi-
cacy of radiotherapy in prostate cancer. Cancer Res (2013) 73(9):2782–94. 
doi:10.1158/0008-5472.CAN-12-3981 
25. Frenguelli BG, Wigmore G, Llaudet E, Dale N. Temporal and mecha-
nistic dissociation of ATP and adenosine release during ischaemia in 
the mammalian hippocampus. J Neurochem (2007) 101(5):1400–13. 
doi:10.1111/j.1471-4159.2007.04425.x 
26. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages 
in tumour progression: implications for new anticancer therapies. J Pathol 
(2002) 196(3):254–65. doi:10.1002/path.1027 
27. O’Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory 
responses. Immunity (2008) 28(4):477–87. doi:10.1016/j.immuni.2008.03.002 
28. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et  al. CCL2 
recruits inflammatory monocytes to facilitate breast-tumour metastasis. 
Nature (2011) 475(7355):222–5. doi:10.1038/nature10138 
29. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage 
population mediates metastatic breast cancer cell extravasation, estab-
lishment and growth. PLoS One (2009) 4(8):e6562. doi:10.1371/journal. 
pone.0006562 
30. Pollard JW. Macrophages define the invasive microenvironment in breast 
cancer. J Leukoc Biol (2008) 84(3):623–30. doi:10.1189/jlb.1107762 
31. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages 
regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 
(2006) 66(23):11238–46. doi:10.1158/0008-5472.CAN-06-1278 
32. Vatner RE, Formenti SC. Myeloid-derived cells in tumors: effects of radiation. 
Semin Radiat Oncol (2015) 25(1):18–27. doi:10.1016/j.semradonc.2014. 
07.008 
33. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et  al. Low-
dose irradiation programs macrophage differentiation to an iNOS(+)/M1 
phenotype that orchestrates effective T  cell immunotherapy. Cancer Cell 
(2013) 24(5):589–602. doi:10.1016/j.ccr.2013.09.014 
34. Hamilton JA. Colony-stimulating factors in inflammation and autoimmu-
nity. Nat Rev Immunol (2008) 8(7):533–44. doi:10.1038/nri2356 
35. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and 
inflammation. Curr Opin Immunol (2006) 18(1):39–48. doi:10.1016/j.coi. 
2005.11.006 
36. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon 
DL, et  al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting 
CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 
(2010) 115(7):1461–71. doi:10.1182/blood-2009-08-237412 
37. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, 
et al. Leukocyte complexity predicts breast cancer survival and functionally 
regulates response to chemotherapy. Cancer Discov (2011) 1(1):54–67. 
doi:10.1158/2159-8274.CD-10-0028 
38. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth 
factor CSF-1 in mammary gland development and tumor progression. 
J Mammary Gland Biol Neoplasia (2002) 7(2):147–62. doi:10.102
3/A:1020399802795 
39. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, et al. 
Analysis of stromal signatures in the tumor microenvironment of ductal car-
cinoma in situ. Breast Cancer Res Treat (2010) 123(2):397–404. doi:10.1007/
s10549-009-0654-0 
40. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, et  al. The 
macrophage colony-stimulating factor 1 response signature in breast carci-
noma. Clin Cancer Res (2009) 15(3):778–87. doi:10.1158/1078-0432.CCR- 
08-1283 
41. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. Tumor-
derived CCL2 mediates resistance to radiotherapy in pancreatic ductal ade-
nocarcinoma. Clin Cancer Res (2017) 23(1):137–48. doi:10.1158/1078-0432.
CCR-16-0870
42. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, 
et  al. Inflammatory monocyte mobilization decreases patient survival in 
pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res 
(2013) 19(13):3404–15. doi:10.1158/1078-0432.CCR-13-0525 
43. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et  al. Targeting of tumour-infil-
trating macrophages via CCL2/CCR2 signalling as a therapeutic strategy 
against hepatocellular carcinoma. Gut (2017) 66(1):157–67. doi:10.1136/
gutjnl-2015-310514 
44. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, et al. 
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody 
against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant 
prostate cancer. Invest New Drugs (2013) 31(3):760–8. doi:10.1007/
s10637-012-9869-8 
45. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, et al. Effect 
of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in 
individuals at atherosclerotic risk and with a single nucleotide polymorphism 
of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol 
(2011) 107(6):906–11. doi:10.1016/j.amjcard.2010.11.005 
46. de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling 
H, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria 
in patients with type 2 diabetes and nephropathy: a randomised trial. 
Lancet Diabetes Endocrinol (2015) 3(9):687–96. doi:10.1016/S2213-8587 
(15)00261-2 
9Wennerberg et al. Barriers to Radiation-Induced In Situ Tumor Vaccination
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 229
47. Ishikawa H, Sakurai H, Hasegawa M, Mitsuhashi N, Takahashi M, Masuda N, 
et al. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free 
survival after radiation therapy alone in stage IIIB cervical squamous cell 
carcinoma. Int J Radiat Oncol Biol Phys (2004) 60(2):513–21. doi:10.1016/j.
ijrobp.2004.03.025 
48. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et  al. 
Expression of hypoxia-inducible factor-1alpha: a novel predictive and 
prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer 
Res (2001) 61(7):2911–6. 
49. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to 
regulate vascular radiosensitivity in tumors: role of reoxygenation, free 
radicals, and stress granules. Cancer Cell (2004) 5(5):429–41. doi:10.1016/
S1535-6108(04)00115-1 
50. Kim YH, Yoo KC, Cui YH, Uddin N, Lim EJ, Kim MJ, et  al. Radiation 
promotes malignant progression of glioma cells through HIF-1alpha 
stabilization. Cancer Lett (2014) 354(1):132–41. doi:10.1016/j.canlet. 
2014.07.048 
51. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et  al. 
PD-L1 is a novel direct target of HIF-1alpha, and its blockade under 
hypoxia enhanced MDSC-mediated T  cell activation. J Exp Med (2014) 
211(5):781–90. doi:10.1084/jem.20131916 
52. Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of 
hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 
(2014) 74(3):665–74. doi:10.1158/0008-5472.CAN-13-0992 
53. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. 
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) 
cells. Nature (2011) 475(7355):226–30. doi:10.1038/nature10169 
54. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo 
DG, et al. Macrophage expression of hypoxia-inducible factor-1 alpha sup-
presses T-cell function and promotes tumor progression. Cancer Res (2010) 
70(19):7465–75. doi:10.1158/0008-5472.CAN-10-1439 
55. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. 
Tumor hypoxia does not drive differentiation of tumor-associated macro-
phages but rather fine-tunes the M2-like macrophage population. Cancer Res 
(2014) 74(1):24–30. doi:10.1158/0008-5472.CAN-13-1196 
56. Corzo CA, Thomas C, Lily L, Matthew JC, Je-In Y, Pingyan C, et al. HIF-
1alpha regulates function and differentiation of myeloid-derived suppressor 
cells in the tumor microenvironment. J Exp Med (2010) 207(11):2439–53. 
doi:10.1084/jem.20100587 
57. Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, et  al. 
Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune 
suppressor cells and compromises NK cell cytotoxicity in the premetastatic 
niche. Cancer Res (2012) 72(16):3906–11. doi:10.1158/0008-5472.CAN- 
11-3873 
58. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, 
et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation 
and tumour angiogenesis. Nature (1998) 394(6692):485–90. doi:10.1038/ 
28867 
59. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, et al. HIF1alpha induces 
the recruitment of bone marrow-derived vascular modulatory cells to 
regulate tumor angiogenesis and invasion. Cancer Cell (2008) 13(3):206–20. 
doi:10.1016/j.ccr.2008.01.034 
60. Ahn GO, Seita J, Hong BJ, Kim YE, Bok S, Lee CJ, et  al. Transcriptional 
activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes 
angiogenesis through VEGF and S100A8. Proc Natl Acad Sci U S A (2014) 
111(7):2698–703. doi:10.1073/pnas.1320243111 
61. Lund EL, Høg A, Olsen MW, Hansen LT, Engelholm SA, Kristjansen PE. 
Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by 
hypoxia and ionizing radiation in human glioblastoma. Int J Cancer (2004) 
108(6):833–8. doi:10.1002/ijc.11662 
62. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. 
Endocr Rev (1997) 18(1):4–25. doi:10.1210/edrv.18.1.0287 
63. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, 
et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory 
T-cell proliferation in colorectal cancer. Cancer Res (2013) 73(2):539–49. 
doi:10.1158/0008-5472.CAN-12-2325 
64. Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, Nakano K, et  al. 
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 
(2010) 40(1):197–203. doi:10.1002/eji.200939887 
65. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, et al. Distinct 
roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated 
with elevated levels of VEGF. Blood (2007) 110(2):624–31. doi:10.1182/
blood-2007-01-065714 
66. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular 
endothelial growth factor inhibits the development of dendritic cells and 
dramatically affects the differentiation of multiple hematopoietic lineages 
in vivo. Blood (1998) 92(11):4150–66. 
67. Horikawa N, Abiko K, Matsumura N, Hamanishi J, Baba T, Yamaguchi K, 
et  al. Expression of vascular endothelial growth factor in ovarian cancer 
inhibits tumor immunity through the accumulation of myeloid-derived 
suppressor cells. Clin Cancer Res (2017) 23(2):587–99. doi:10.1158/1078-
0432.CCR-16-0387
68. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, et  al. 
VEGF directly suppresses activation of T cells from ovarian cancer patients 
and healthy individuals via VEGF receptor type 2. Int J Cancer (2012) 
130(4):857–64. doi:10.1002/ijc.26094 
69. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et  al. 
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells 
in tumors. J Exp Med (2015) 212(2):139–48. doi:10.1084/jem.20140559 
70. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, 
et  al. Tumor endothelium FasL establishes a selective immune barrier 
promoting tolerance in tumors. Nat Med (2014) 20(6):607–15. doi:10.1038/ 
nm.3541 
71. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum 
RM, et al. Blockage of the vascular endothelial growth factor stress response 
increases the antitumor effects of ionizing radiation. Cancer Res (1999) 
59(14):3374–8. 
72. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. 
Inhibition of vascular endothelial growth factor receptor signaling leads to 
reversal of tumor resistance to radiotherapy. Cancer Res (2001) 61(6):2413–9. 
73. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of 
adenosine in cancer. Curr Opin Pharmacol (2016) 29:7–16. doi:10.1016/j.
coph.2016.04.001 
74. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, 
et  al. Physiological control of immune response and inflammatory tissue 
damage by hypoxia-inducible factors and adenosine A2A receptors. Annu 
Rev Immunol (2004) 22:657–82. doi:10.1146/annurev.immunol.22.012703. 
104731 
75. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et  al. 
Anticancer chemotherapy-induced intratumoral recruitment and dif-
ferentiation of antigen-presenting cells. Immunity (2013) 38(4):729–41. 
doi:10.1016/j.immuni.2013.03.003 
76. Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in 
NLRP3 inflammasome activation. Front Immunol (2013) 3:414. doi:10.3389/
fimmu.2012.00414
77. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. 
Molecular determinants of immunogenic cell death elicited by anticancer 
chemotherapy. Cancer Metastasis Rev (2011) 30(1):61–9. doi:10.1007/
s10555-011-9273-4 
78. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. 
Tumor cell death and ATP release prime dendritic cells and efficient anti-
cancer immunity. Cancer Res (2010) 70(3):855–8. doi:10.1158/0008-5472.
CAN-09-3566 
79. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic sig-
naling in thrombosis, inflammation, and immunity. Adv Pharmacol (2011) 
61:301–32. doi:10.1016/B978-0-12-385526-8.00010-2 
80. Palmer TM, Trevethick MA. Suppression of inflammatory and immune 
responses by the A(2A) adenosine receptor: an introduction. Br J Pharmacol 
(2008) 153(Suppl 1):S27–34. doi:10.1038/sj.bjp.0707524 
81. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The 
development and immunosuppressive functions of CD4(+) CD25(+) 
FoxP3(+) regulatory T cells are under influence of the adenosine-A2A ade-
nosine receptor pathway. Front Immunol (2012) 3:190. doi:10.3389/fimmu. 
2012.00190 
82. Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A 
receptor suppresses T and NK cell responses in the solid tumor microen-
vironment. Cancer Res (2014) 74(24):7250–9. doi:10.1158/0008-5472.CAN- 
13-3583 
10
Wennerberg et al. Barriers to Radiation-Induced In Situ Tumor Vaccination
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 229
83. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, et  al. 
Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pul-
monary endothelial cells. Proc Natl Acad Sci U S A (2009) 106(26):10684–9. 
doi:10.1073/pnas.0901326106 
84. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 
promotes anthracycline resistance and poor prognosis in triple negative 
breast cancer. Proc Natl Acad Sci U S A (2013) 110(27):11091–6. doi:10.1073/
pnas.1222251110 
85. Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical sig-
nificance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma. 
World J Gastroenterol (2013) 19(12):1912–8. doi:10.3748/wjg.v19.i12.1912 
86. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, et al. High expression 
of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg 
Oncol (2012) 106(2):130–7. doi:10.1002/jso.23056 
87. Xiong L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key regulators of 
TGF-1-induced epithelial-mesenchymal transition (EMT) are associated 
with tumor progression and survival of patients with gallbladder cancer. Cell 
Tissue Res (2014) 355(2):365–74. doi:10.1007/s00441-013-1752-1 
88. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, 
et  al. CD73-deficient mice have increased antitumor immunity and are 
resistant to experimental metastasis. Cancer Res (2011) 71(8):2892–900. 
doi:10.1158/0008-5472.CAN-10-4246 
89. Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, et al. 
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates 
their immunosuppressive activity. Cancer Immunol Res (2015) 3(3):254–65. 
doi:10.1158/2326-6066.CIR-14-0018 
90. Umansky V, Shevchenko I, Bazhin AV, Utikal J. Extracellular adenosine 
metabolism in immune cells in melanoma. Cancer Immunol Immunother 
(2014) 63(10):1073–80. doi:10.1007/s00262-014-1553-8 
91. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, 
Ren J, et al. Generation and accumulation of immunosuppressive adenosine 
by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2010) 
285(10):7176–86. doi:10.1074/jbc.M109.047423 
92. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Müller CE, Sträter N. Crystal 
structure of the human ecto-5′-nucleotidase (CD73): insights into the regula-
tion of purinergic signaling. Structure (2012) 20(12):2161–73. doi:10.1016/j.
str.2012.10.001 
93. Strater N. Ecto-5′-nucleotidase: structure function relationships. Purinergic 
Signal (2006) 2(2):343–50. doi:10.1007/s11302-006-9000-8 
94. Whiteside TL, Mandapathil M, Schuler P. The role of the adenosinergic path-
way in immunosuppression mediated by human regulatory T cells (Treg). 
Curr Med Chem (2011) 18(34):5217–23. doi:10.2174/092986711798184334 
95. Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, 
Bouïs D, et  al. Self-regulation of inflammatory cell trafficking in mice by 
the leukocyte surface apyrase CD39. J Clin Invest (2009) 119(5):1136–49. 
doi:10.1172/JCI36433 
96. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, et al. Purinergic signaling: 
a fundamental mechanism in neutrophil activation. Sci Signal (2010) 
3(125):ra45. doi:10.1126/scisignal.2000549 
97. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni 
I, et  al. Adenosinergic regulation of the expansion and immunosuppres-
sive activity of CD11b+Gr1+ cells. J Immunol (2011) 187(11):6120–9. 
doi:10.4049/jimmunol.1101225 
98. Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the anti-
tumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 
19(20):5626–35. doi:10.1158/1078-0432.CCR-13-0545 
99. Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, 
et  al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 
through enhanced antitumor T-cell responses. Cancer Immunol Res (2015) 
3(5):506–17. doi:10.1158/2326-6066.CIR-14-0211 
100. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the 
therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. 
Am J Cancer Res (2014) 4(2):172–81. 
101. Wennerberg E, Kawashima N, Demaria S. Adenosine regulates radiation 
therapy-induced anti-tumor immunity. J Immunother Cancer (2015) 3(Suppl 
2):378. doi:10.1186/2051-1426-3-S2-P378 
102. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth 
factor-beta regulation of immune responses. Annu Rev Immunol (2006) 
24:99–146. doi:10.1146/annurev.immunol.24.021605.090737 
103. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. 
Annu Rev Immunol (1998) 16:137–61. doi:10.1146/annurev.immunol. 
16.1.137 
104. Gros MJ, Naquet P, Guinamard RR. Cell intrinsic TGF-beta 1 regulation 
of B  cells. J Immunol (2008) 180(12):8153–8. doi:10.4049/jimmunol.180. 
12.8153 
105. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 
controls T  cell tolerance and regulates Th1- and Th17-cell differentiation. 
Immunity (2007) 26(5):579–91. doi:10.1016/j.immuni.2007.03.014 
106. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated 
self-reactivity. Nat Rev Immunol (2007) 7(6):443–53. doi:10.1038/nri2095 
107. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et  al. 
Targeted disruption of the mouse transforming growth factor-beta 1 gene 
results in multifocal inflammatory disease. Nature (1992) 359(6397):693–9. 
doi:10.1038/359693a0 
108. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA. A role for TGF-beta in 
the generation and expansion of CD4+CD25+ regulatory T  cells from 
human peripheral blood. J Immunol (2001) 166(12):7282–9. doi:10.4049/
jimmunol.166.12.7282 
109. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of 
peripheral CD4+CD25- naive T  cells to CD4+CD25+ regulatory T  cells 
by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 
198(12):1875–86. doi:10.1084/jem.20030152 
110. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T  cell func-
tions during tumor evasion of immune surveillance. Cancer Cell (2005) 
8(5):369–80. doi:10.1016/j.ccr.2005.10.012 
111. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold 
SP, et  al. Generation of anti-inflammatory adenosine by leukocytes is 
regulated by TGF-beta. Eur J Immunol (2011) 41(10):2955–65. doi:10.1002/ 
eji.201141512 
112. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. 
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive 
activity via the regulation of ectonucleotidase expression. Immunity (2012) 
36(3):362–73. doi:10.1016/j.immuni.2011.12.019 
113. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization 
of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” 
TAN. Cancer Cell (2009) 16(3):183–94. doi:10.1016/j.ccr.2009.06.017 
114. Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, et al. 
Transforming growth factor beta signaling inhibitor, SB-431542, induces 
maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep 
(2010) 24(6):1637–43. doi:10.3892/or_00001028 
115. Gratchev A. TGF-beta signalling in tumour associated macrophages. 
Immunobiology (2017) 222(1):75–81. doi:10.1016/j.imbio.2015.11.016 
116. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polariza-
tion: tumor-associated macrophages as a paradigm for polarized M2 mono-
nuclear phagocytes. Trends Immunol (2002) 23(11):549–55. doi:10.1016/
S1471-4906(02)02302-5 
117. Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, et  al. Tumor-
associated neutrophils display a distinct N1 profile following TGFbeta modu-
lation: a transcriptomics analysis of pro- vs. antitumor TANs. Oncoimmunology 
(2016) 5(11):e1232221. doi:10.1080/2162402X.2016.1232221 
118. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming 
growth factor-beta activation in irradiated murine mammary gland. J Clin 
Invest (1994) 93(2):892–9. doi:10.1172/JCI117045 
119. Jobling MF, Mott JD, Finnegan MT, Jurukovski V, Erickson AC, Walian PJ, 
et al. Isoform-specific activation of latent transforming growth factor beta 
(LTGF-beta) by reactive oxygen species. Radiat Res (2006) 166(6):839–48. 
doi:10.1667/RR0695.1 
120. Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti 
SC, et al. TGFbeta is a master regulator of radiation therapy-induced antitu-
mor immunity. Cancer Res (2015) 75(11):2232–42. doi:10.1158/0008-5472.
CAN-14-3511 
121. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle 
EJ, et  al. Acquired resistance to fractionated radiotherapy can be over-
come by concurrent PD-L1 blockade. Cancer Res (2014) 74(19):5458–68. 
doi:10.1158/0008-5472.CAN-14-1258 
122. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et  al. 
Colocalization of inflammatory response with B7-h1 expression in 
human melanocytic lesions supports an adaptive resistance mechanism 
11
Wennerberg et al. Barriers to Radiation-Induced In Situ Tumor Vaccination
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 229
of immune escape. Sci Transl Med (2012) 4(127):127ra37. doi:10.1126/
scitranslmed.3003689 
123. Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia 
inducible factor in clear cell renal cell carcinoma. Int J Cancer (2016) 
139(2):396–403. doi:10.1002/ijc.30077 
124. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination 
of immunotherapy with radiotherapy. J Immunother Cancer (2016) 4:51. 
doi:10.1186/s40425-016-0156-7 
125. Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy 
and immune checkpoint inhibitors. Semin Radiat Oncol (2015) 25(1):28–33. 
doi:10.1016/j.semradonc.2014.07.004 
126. Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, et  al. 
Trial watch: immunotherapy plus radiation therapy for oncological 
indications. Oncoimmunology (2016) 5(9):e1214790. doi:10.1080/21624
02X.2016.1214790 
127. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab 
plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 
(2014) 2(7):632–42. doi:10.1158/2326-6066.CIR-14-0053 
128. Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, et al. 
VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors 
associated with enhancing lymphocyte infiltration and humoral recognition 
in melanoma. Cancer Immunol Res (2016) 4(10):858–68. doi:10.1158/2326-
6066.CIR-16-0084 
129. Melsens E, Verberckmoes B, Rosseel N, Vanhove C, Descamps B, Pattyn P, 
et al. The VEGFR inhibitor cediranib improves the efficacy of fractionated 
radiotherapy in a colorectal cancer xenograft model. Eur Surg Res (2016) 
58(3–4):95–108. doi:10.1159/000452741 
130. Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane 
J, et  al. First-in-human dose study of the novel transforming growth 
factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients 
with advanced cancer and glioma. Clin Cancer Res (2015) 21(3):553–60. 
doi:10.1158/1078-0432.CCR-14-1380 
131. Kovacs RJ, Maldonado G, Azaro A, Fernández MS, Romero FL, Sepulveda-
Sánchez JM, et  al. Cardiac safety of TGF-beta receptor I kinase inhibitor 
LY2157299 monohydrate in cancer patients in a first-in-human dose study. 
Cardiovasc Toxicol (2015) 15(4):309–23. doi:10.1007/s12012-014-9297-4 
132. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase 
I study of GC1008 (fresolimumab): a human anti-transforming growth 
factor-beta (TGFbeta) monoclonal antibody in patients with advanced 
malignant melanoma or renal cell carcinoma. PLoS One (2014) 9(3):e90353. 
doi:10.1371/journal.pone.0090353 
133. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory 
micro-environment in tumor progression: the role of tumor-associated 
macrophages. Crit Rev Oncol Hematol (2008) 66(1):1–9. doi:10.1016/j.
critrevonc.2007.07.004 
134. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, et al. 
Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. 
N Engl J Med (2015) 373(5):428–37. doi:10.1056/NEJMoa1411366 
135. Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF. CD39: a com-
plementary target to immune checkpoints to counteract tumor-mediated 
immunosuppression. Oncoimmunology (2015) 4(5):e1003015. doi:10.1080/
2162402X.2014.1003015 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Wennerberg, Lhuillier, Vanpouille-Box, Pilones, García-Martínez, 
Rudqvist, Formenti and Demaria. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
